Who are HES 10%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HES 130/0.42 + electrolyte solution, balanced 6% hydroxyethylstarch 130/0.4, Hydroxyethylstarch 6% 130/0.4.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hes-10.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

HES 10% — Competitive Intelligence Brief

HES 10% (HES 10%) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Synthetic colloid plasma volume expander. Area: Critical Care / Anesthesia.

marketed Synthetic colloid plasma volume expander Critical Care / Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

HES 10% (HES 10%) — B. Braun Melsungen AG. HES 10% is a hydroxyethyl starch colloid that expands intravascular volume by increasing plasma oncotic pressure to maintain fluid balance.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
HES 10% TARGET	HES 10%	B. Braun Melsungen AG	marketed	Synthetic colloid plasma volume expander
HES 130/0.42 + electrolyte solution	HES 130/0.42 + electrolyte solution	B. Braun Melsungen AG	marketed	Synthetic colloid plasma volume expander
balanced 6% hydroxyethylstarch 130/0.4	balanced 6% hydroxyethylstarch 130/0.4	University Hospital Muenster	marketed	Synthetic colloid plasma volume expander
Hydroxyethylstarch 6% 130/0.4	Hydroxyethylstarch 6% 130/0.4	Medical University of Vienna	marketed	Synthetic colloid plasma volume expander

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Synthetic colloid plasma volume expander class)

B. Braun Melsungen AG · 2 drugs in this class
Medical University of Vienna · 1 drug in this class
University Hospital Muenster · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HES 10% — Competitive Intelligence Brief. https://druglandscape.com/ci/hes-10. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab